At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 641 enrolled
Drug / intervention
florbetapir (18F)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline
In Brief
A Phase 4 clinical trial evaluating florbetapir (18F) for Alzheimer's Disease. Completed, enrolled 641 participants across 57 sites in 3 countries.
Detailed Summary
This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesFrance, Italy, United States
CollaboratorsEli Lilly and Company
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedOct 2012
Primary CompletionApr 2015
TodayJul 2026
First PostedOct 10, 2012
Enrollment StartOct 1, 2012
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 13.7 years ago
Interventions
florbetapir (18F)drug
Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration